StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)
September 22, 2026 10:21 AM
Stifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Celldex Therapeutics (NASDAQ: CLDX).The analyst comments "CLDX ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
